Posts in the “Clinical Trials Clinical Trials” category:

Online Screening for Rare Lung Cancer Mutation Opens Door to New Kind of Clinical Trial

Posted by Samantha Powell on August 22nd, 2014 |

In the previous few years, several breakthrough treatments have become available for key subtypes of lung cancer. Patients who may benefit from these treatments can be pre-identified by looking for defined genetic abnormalities in their cancer. For example, patients whose lung cancer is driven by rearrangement of the gene ALK derive significant benefit from the […]

NCI Launches Molecular Medicine Clinical Trials; Response Genetics Nabs Profiling Contract

Posted by Samantha Powell on August 18th, 2014 |

The National Cancer Institute said today it has launched new clinical trials that will use tumor sequencing and genetic markers to help determine whether therapies targeting genetic alterations can prevent lung cancer recurrence. Separately, Response Genetics said it has been awarded a “multi-million dollar” subcontract from Leidos Biomedical Research, a contractor for the NCI-sponsored Frederick […]

Ambitious Lung-MAP Trial Launched With Five Novel Drugs

Posted by Samantha Powell on August 1st, 2014 |

Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial, an innovative biomarker-driven study that aims to improve the drug development process while exploring therapeutic options for this challenging malignancy. Plans call for enrolling up to 5000 patients through more […]

Brachytherapy with Sublobar Resection Fails to Improve NSCLC Recurrence Rates

Posted by Samantha Powell on July 4th, 2014 |

Brachytherapy did not reduce rates of local recurrence after sublobar resection in patients with non–small-cell lung cancer (NSCLC), according to results of a new randomized phase III study. Previous work has suggested an association between sublobar resection and higher locoregional recurrence rates compared with lobectomy; as a result, the procedure is usually reserved for high-risk […]

Ambitious ‘Lung-MAP’ Trial Aims to Evaluate Biomarkers and New Drugs in Squamous Cell Lung Cancer

Posted by Samantha Powell on June 23rd, 2014 |

This month, the National Cancer Institute (NCI), along with the FDA, the Southwest Oncology Group (SWOG), several private foundations and five pharmaceutical companies, launched a prospective, biomarker-driven study of new drugs for squamous cell lung cancer. The Lung-MAP trial is remarkable for its collaborative nature, and scope. The study will identify “actionable” molecular abnormalities in […]

Genprex Begins Phase 2 Lung Cancer Trial

Posted by Samantha Powell on May 20th, 2014 |

Date: 5/20/14 Outlet Full Name: Drug Discovery and Development Author: No author http://www.dddmag.com/news/2014/05/genprex-begins-phase-2-lung-cancer-trial Genprex Inc. announced that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex in combination with erlotinib (Tarceva) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits […]

New Video Delves Into the Promise of Lung Cancer Immunotherapy Clinical Trials for Patients With Non-Small Cell Lung Cancer

Posted by Samantha Powell on May 15th, 2014 |

Date: 5/15/14 Outlet Full Name: Digital Journal Author: No author http://www.digitaljournal.com/pr/1922309 A recently released video on cancer immunotherapy is offering new hope to patients with non-small cell lung cancer (NSCLC), the type of cancer which makes up 85% to 90% of all lung cancer cases in the US and claims more lives each year than […]

Drug Combo May Knock Down Lung Cancer

Posted by Samantha Powell on May 12th, 2014 |

Date: 4/20/14 Outlet Full Name: U-T San Diego Author: Bradley Fikes http://www.utsandiego.com/news/2014/Apr/20/cancer-velcade-cheresh-seguin-ucsd/ Some drug-resistant cancers of the lung, pancreas and breast might be made vulnerable again by treating them with a medication already approved for another type of cancer, according to a new study led by scientists at UC San Diego. Researchers at UCSD Moores […]

AstraZeneca Starts Phase III Immunotherapy Study for MEDI4736 in Patients With Lung Cancer

Posted by Samantha Powell on May 8th, 2014 |

News Headline: AstraZeneca Starts Phase III Immunotherapy Study for MEDI4736 in Patients With Lung Cancer Date: 5/8/14 Outlet Full Name: Pharmaceutical Processing Author: No author http://www.pharmpro.com/news/2014/05/astrazeneca-starts-phase-iii-immunotherapy-study-medi4736-patients-lung-cancer AstraZeneca today announced the start of the Phase III program for MEDI4736, an immunotherapy in development for the treatment of non-small cell lung cancer (NSCLC) and other cancers. The […]

Lung Cancer May Be Weakened by Drug Combination

Posted by Samantha Powell on May 5th, 2014 |

News Headline: Lung Cancer May Be Weakened by Drug Combination Date: 5/5/14 Outlet Full Name: Chicago Tribune Author: Elijah Lamond http://www.chicagotribune.com/brandpublishing/empowered-doctor/chi-lung-cancer-may-be-weakened-by-drug-combination-20140505,0,6351912.story Lung cancer patients who have a drug-resistant version of the disease have very few options for treatment. This reality may be changing in near future with a discovery by researchers at UC San Diego. […]